inVentiv Group Holdings filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were mentioned in this filing, but in the previous filing the offering was valued up to $100 million. The company intends to list on the New York Stock Exchange under the symbol IVH.
The underwriters for the offering are Credit Suisse, Morgan Stanley, Goldman Sachs, Jefferies, Citigroup, Merrill Lynch, Barclays, Wells Fargo, Baird and William Blair.
This is a leading global provider of outsourced clinical development and commercialization services to biopharmaceutical companies. The company is the only provider delivering a full suite of services to enhance clients’ ability to successfully develop, launch and market their products. It offers services on both a standalone basis and as integrated solutions to support clinical development and commercialization.
These solutions are designed to drive greater efficiency and lower costs. inVentiv helped develop or commercialize over 80% of all new molecular entities approved by the U.S. Food and Drug Administration (FDA) and 70% of those approved by the European Medicines Agency (EMA) over the past five years through its innovative model.
In 2015, it served more than 550 client organizations, including all 20 of the largest global biopharmaceutical companies, and it has the ability to service clients in over 90 countries. The company has over 14,000 employees globally, including over 750 M.D.s and Ph.D.s.
In terms of finances, the company’s net revenues increased 10.4% on an as-reported basis (13.0% on a constant currency basis) to $1.994 billion. Clinical segment net revenues increased 8.9% to $947.9 million, and Commercial segment net revenues increased 12.3% to $1.06 billion. The company incurred losses from continuing operations of $18.7 million and $45.0 million for the three months ended March 31, 2016, and 2015, respectively, and $150.6 million and $180.6 million for the year ended December 31, 2015, and 2014.
inVentiv intends to use the net proceeds from this offering to repay certain outstanding indebtedness and for general corporate purposes.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
